survival (version 2.41-2)

pbc: Mayo Clinic Primary Biliary Cirrhosis Data

Description

D This data is from the Mayo Clinic trial in primary biliary cirrhosis (PBC) of the liver conducted between 1974 and 1984. A total of 424 PBC patients, referred to Mayo Clinic during that ten-year interval, met eligibility criteria for the randomized placebo controlled trial of the drug D-penicillamine. The first 312 cases in the data set participated in the randomized trial and contain largely complete data. The additional 112 cases did not participate in the clinical trial, but consented to have basic measurements recorded and to be followed for survival. Six of those cases were lost to follow-up shortly after diagnosis, so the data here are on an additional 106 cases as well as the 312 randomized participants. A nearly identical data set found in appendix D of Fleming and Harrington; this version has fewer missing values.

Usage

pbc

Format

age:	in years
albumin:	serum albumin (g/dl)
alk.phos:	alkaline phosphotase (U/liter)
ascites:	presence of ascites
ast:	aspartate aminotransferase, once called SGOT (U/ml)
bili:	serum bilirunbin (mg/dl)
chol:	serum cholesterol (mg/dl)
copper:	urine copper (ug/day)
edema:	0 no edema, 0.5 untreated or successfully treated
	1 edema despite diuretic therapy
hepato:	presence of hepatomegaly or enlarged liver
id:	case number
platelet:	platelet count
protime:	standardised blood clotting time
sex:	m/f
spiders:	blood vessel malformations in the skin
stage:	histologic stage of disease (needs biopsy)
status:	status at endpoint, 0/1/2 for censored, transplant, dead
time:	number of days between registration and the earlier of death,
	transplantion, or study analysis in July, 1986
trt:	1/2/NA for D-penicillmain, placebo, not randomised
trig:	triglycerides (mg/dl)